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Abstract
 
The migration of antigen-specific T cells to nonlymphoid tissues is thought to be important for
the elimination of foreign antigens from the body. However, recent results showing the migra-
tion of activated T cells into many nonlymphoid tissues raised the possibility that antigen-spe-
cific T cells do not migrate preferentially to nonlymphoid tissues containing antigen. We ad-
dressed this question by tracking antigen-specific CD4 T cells in the whole body after a localized
subcutaneous antigen injection. Antigen-specific CD4 T cells proliferated in the skin-draining
lymph nodes and the cells that underwent the most cell divisions acquired the ability to bind to
CD62P. As time passed, CD62P-binding antigen-specific CD4 T cells with interferon 
 
 
 
 pro-
duction potential accumulated preferentially at the site of antigen injection but only in recipients
that expressed CD62E. Surprisingly, these T cells did not proliferate in the injection site despite
showing evidence of more cell divisions than the T cells in the draining lymph nodes. The re-
sults suggest that the most divided effector CD4 T cells from the lymph nodes enter the site of
antigen deposition via recognition of CD62E on blood vessels and are retained there in a non-
proliferative state via recognition of peptide–major histocompatibility complex II molecules.
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Introduction
 
The elimination of intracellular antigens from the body is
thought to depend on the migration of the activated T cells
to the tissue where antigen is harbored (1). For CD4 T
cells, this process is initiated by dendritic cells that take up
antigen in the tissue where it enters the body and then mi-
grate to the secondary lymphoid organs displaying peptide–
MHC II complexes derived from the antigen (2). CD4 T
cells expressing a complementary TCR, recognize these
complexes, produce growth factors, proliferate (3), and
then many of the progeny migrate into nonlymphoid tissues
including the lungs, liver, intestines, and salivary glands (4).
As the CD4 T cells in nonlymphoid tissues are potent pro-
 
ducers of IL-4 (5, 6) or IFN-
 
 
 
 (4, 7), the purpose of this mi-
gration may be to bring effector T cells into infected tissues
to stimulate the antimicrobial activities of phagocytes.
Activated T cells are able to enter nonlymphoid tissues
due to the induction of surface receptors that are not ex-
pressed on naive T cells. Naive T cells use CD62L, CCR7,
and LFA-1 to recognize and extravasate through the spe-
cialized high endothelial venules of the lymph nodes and
mucosal lymphoid tissues, but lack the molecules needed to
pass out of other types of blood vessels (1, 8). In contrast, a
subset of activated T cells lose CD62L and gain a new set of
selectins, chemokine receptors, and integrins, which allow
these cells to pass through blood vessels and migrate into
the interstitial spaces of nonlymphoid tissues (1, 8).
Activated T cells enter the skin by binding to CD62P
and CD62E on the endothelial cells of inflamed blood
vessels. The binding of activated T cells to CD62P and
CD62E is thought to be mediated by a fucosylated form
 
of CD62P ligand-1 (PSGL-1;
 
*
 
 reference 9), although another
CD62E-binding molecule known as CD62E ligand-1 also
exists (10). PSGL-1 is expressed on naive T cells, but in an
unfucosylated form that does not bind to CD62P or
 
Address correspondence to Marc K. Jenkins, University of Minnesota,
Center for Immunology, MMC 334, 420 Delaware St. S.E., Minneapolis,
MN 55455. Phone: 612-626-2715; Fax: 612-625-2199; E-mail:
marcj@mail.ahc.umn.edu
 
*
 
Abbreviations used in this paper:
 
 B6, C57BL/6; CD62P-Ig, fusion protein
consisting of the extracellular domain of CD62P and human Ig Fc; CFSE,
5- and 6-carboxy-fluorescein succinimidyl ester; DAPI, 4
 
 
 
,6-diamidine-
2
 
 
 
-phenylindole dihydrochloride; PSGL-1, CD62P glycoprotein ligand-1.T
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CD62E (9, 11–13). After TCR and IL-12 receptor signal-
ing, T cells express a fucosyl transferase that adds a fucose
group to PSGL-1, converting it to a form capable of bind-
ing to both CD62P and CD62E (11, 14, 15). Of the acti-
vated CD4 T cells that bind to CD62P 
 
 
 
70% of these cells
also bind to CD62E (16), probably via PSGL-1. The mole-
cule that accounts for the binding of activated T cells to
CD62P alone is unknown.
The importance of CD62E and CD62P to T cell migra-
tion is evidenced by the finding that the migration of Th1
cells into inflamed skin after adoptive transfer is inhibited
when CD62P and/or CD62E are blocked (17, 18). In ad-
dition, the cutaneous hypersensitivity reaction, which is
mediated by T cells, is impaired in mice lacking CD62P
(19), CD62E and CD62P (18, 20, 21), or fucosyl trans-
ferase VII (22), and in mice in which CD62E is blocked
(23, 24). Furthermore, a fraction of the antigen-specific
CD4 T cells in the lymph nodes express fucosylated PSGL-1
several days after subcutaneous injection of antigen (25) as
do the majority of T cells that can be isolated from the skin
(26). It is therefore possible that antigen-stimulated T cells
leave the lymph node during the primary response and use
fucosylated PSGL-1 to enter the site of immunization by
binding to CD62P and CD62E-expressing blood vessels.
Although this is an appealing scenario, it has yet to be dem-
onstrated during an immune response in vivo.
Although activated T cells migrate into nonlymphoid
tissues, it is not clear that nonlymphoid tissues containing
antigen are preferred. Topham et al. (27) found that anti-
gen-experienced CD8 T cells migrated into inflamed
lungs whether or not the relevant antigen was present in
the lungs. Although autoantigen-specific T cells infiltrate
the organ expressing the autoantigen (28, 29), it is possible
that this reflects generalized migration to nonlymphoid tis-
sues rather than specific migration to an antigen-contain-
ing site. Recent studies in which activated T cells were
shown to migrate into many nonlymphoid organs after
systemic administration of antigen (4, 30), did not shed
light on this issue because antigen was not concentrated in
a defined location. Thus, it was not possible to determine
whether or not the T cells accumulated to a greater extent
in organs that contained antigen compared with those that
did not.
We addressed this question by quantifying antigen-spe-
cific CD4 T cells in the whole body after a localized subcu-
taneous injection of antigen. The results show the combined
action of CD62E-dependent migration and antigen-depen-
dent retention cause the injection site to become the major
nonlymphoid tissue in which antigen-specific CD4 T cells
accumulate during the primary response in the skin.
 
Materials and Methods
 
Mice.
 
DO11.10 BALB/c (31), DO11.10 BALB/c RAG2-
deficient, and OT-II C57BL/6 (B6).PL (32) mice were bred in a
specific pathogen-free facility according to National Institutes of
Health guidelines. B6, BALB/c, and CD62P-deficient B6 mice
were purchased from The Jackson Laboratory. B6 mice deficient
 
in CD62E only or both CD62P and CD62E (33) were provided
by D.C. Bullard (University of Alabama at Birmingham).
 
Adoptive Transfer.
 
Single-cell suspensions of spleen and lymph
nodes were prepared from DO11.10 BALB/c, DO11.10 RAG2-
deficient BALB/c, or OT-II B6.PL mice. A sample was stained
to obtain the percentage of CD4 T cells expressing the transgenic
TCR. For DO11.10 mice, cells were stained with CyChrome-
labeled anti-CD4 mAb (BD Biosciences) and FITC-labeled KJ1–26
mAb (Caltag), which specifically recognizes the DO11.10 TCR
(34). For OT-II mice, cells were stained with CyChrome-labeled
anti-CD4 mAb, FITC-labeled anti-V
 
 
 
2 mAb, and phycoery-
thrin-labeled anti-Thy1.1 mAb (all from BD Biosciences). Re-
cipient mice were injected with 3 
 
 
 
 10
 
6
 
 TCR transgenic CD4 T
cells in 0.3 ml of PBS. For 5- and 6-carboxy-fluorescein succin-
imidyl ester (CFSE; Molecular Probes) labeling, cells were incu-
bated with 5 
 
 
 
M CFSE in HBSS for 10 min at 37
 
 
 
C. Cells were
then washed with medium containing FCS and PBS before adop-
tive transfer.
 
Immunizations.
 
Mice were injected with chicken OVA pep-
tide (residues 323–339; Research Genetics) either intravenously
or subcutaneously, 1 d after receiving TCR transgenic T cells.
For intravenous injections, mice received 100 
 
 
 
g of OVA pep-
tide with or without LPS (25 
 
 
 
g, serotype 
 
Escherichia coli
 
 026:B6,
Difco Laboratories) in 0.3 ml of PBS via the tail vein. Alterna-
tively, mice received 50 or 100 
 
 
 
g of OVA peptide emulsified in
IFA (Sigma-Aldrich) in 20 or 40 
 
 
 
l, respectively, in the tail. In
some cases mice were injected at two subcutaneous sites on the
same tail. One site received 50 
 
 
 
g of OVA peptide in 20 
 
 
 
l of
IFA, and the other received 20 
 
 
 
l of IFA alone. These two sites
were separated by 1 cm of normal tail tissue.
 
Whole Mouse Staining.
 
Mice were killed, perfused with PBS
through the left ventricle of the heart, and frozen in O.C.T. em-
bedding compound. 10 
 
 
 
m sections were cut with a LKB 2250
cryomicrotome as described previously (4, 35). Sections were de-
hydrated and fixed in formaldehyde and then Fc-, biotin-, or avi-
din-binding sites were blocked as described previously (4). After a
brief wash with PBS, sections were incubated for 20 min with
biotin labeled anti-Thy1.1 monoclonal antibody. The sections
were then incubated with streptavidin-peroxidase followed by
biotinyl tyramide from the TSA™-Biotin kit (NEN Life Science
Products) according to manufacturer instructions. Deposited
biotin was detected by streptavidin-Cy3 (Caltag), and the sections
were counterstained for 5 min with a 10 
 
 
 
g/ml solution of 4
 
 
 
,6-
diamidine-2
 
 
 
-phenylindole dihydrochloride (DAPI; Roche Ap-
plied Science) in PBS. Sections were mounted on glass plates and
covered with Vectashield (Vector Laboratories) before application
of a coverslip.
 
Whole Mouse Imaging.
 
Images of whole mouse sections were
captured by a CCD camera attached to an Olympus B-60 fluo-
rescence microscope equipped with an automated stage driven by
Metamorph software (Universal Imaging Corp.). A slide with an
affixed whole mouse section was mounted on the stage and posi-
tioned such that the stage was in the top, left position. This posi-
tion was defined as the origin. Beginning at the origin, a series of
DAPI images covering 
 
 
 
3/4 of the section was collected in a
pattern of 14 rows, each consisting of 37 images. Once the DAPI
images were obtained, the stage was returned to the origin, and
the same set of Cy3 images was collected. Because it was not pos-
sible to image the entire mouse in one pass, the slide was moved
and an additional 5–7 rows were imaged to capture the full sec-
tion. Photoshop 5.5 software (Adobe Systems Inc.) was used to
assemble the 
 
 
 
700 individual images into single composite DAPI
or Cy3 images. The DAPI images are assembled first. Due to can-T
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vas size constraints in Photoshop 5.5, each individual image was
reduced in size to a width of 2 inches. The individual images
from each row were assembled and then stacked sequentially to
produce the final composite DAPI image. Similar actions were
used to assemble the Cy3 images except that operations were first
performed to reduce background fluorescence. The background
signal was blanked by setting the threshold so that no red pixels
were detected on an area of tissue that had no punctate red ob-
jects. The Image/Adjust/Invert function was used to convert the
remaining red objects to black. Individual T cells (based on rim
staining) where then identified in the lymphoid tissues and the
average number of pixels per T cell was determined using the Im-
age/Histogram function. Objects that had 50% more or less pixels
than this average were eliminated using the Digimarc Plug-in fea-
ture, IP•Features/Cutoff. This step eliminated noncell sized arti-
facts. The remaining cellular objects were converted back to red
using the Select/Color range/Reds function in Photoshop and
increased fivefold in diameter using the Select/Modify/Expand
feature so that individual T cells could be seen on the composite
image. The individual Cy3 images were then assembled as de-
scribed above, and the resulting Cy3 composite was overlaid on
the relevant DAPI composite to produce the final merged com-
posite of each section.
 
Quantification of Antigen-specific T Cells in Individual Tissues.
 
Sections (6–10 
 
 
 
m) of explanted tail, spleen, lung, or small intes-
tine from recipients of DO11.10 or OT-II cells were prepared
using a Leica CM 1800 cryomicrotome (Leica), and placed on
charged glass slides (Fisher Scientific). After blocking, sections
were stained sequentially with biotin-labeled KJ1–26 mAb or
biotin-labeled anti-Thy 1.1 mAb, streptavidin-peroxidase, bio-
tinyl tyramide, streptavidin-Cy3, and DAPI as described above.
Digital images were prepared and the background was adjusted as
for the whole mouse images. An average pixel/cell cutoff was ap-
plied to eliminate artifacts and cells that were not in the plane of
the section, preventing overestimation of the total cells in the or-
gan. This was done as described above, except that the cutoff was
applied only to objects below the average pixel value, so as not to
eliminate clusters of cells. The cell-sized objects that remained
were counted using the Digimarc Plug-in feature IP•Features/
Count marks option. On sections where TCR transgenic cells
were very abundant and in contact with one another, the same
cutoff was used, but instead of using the count marks option, the
total number of red pixels on the section obtained using the Se-
lect/Color range and Image/Histogram options in Photoshop
was divided by the average pixels/cell value. This gave a value for
the total number of TCR transgenic cells per section. In the case
of tail cross sections, this value was multiplied by the total num-
ber of sections along the length of the injection site. For the other
organs, which have irregular shapes, the fractional area of repre-
sentative sections occupied by TCR transgenic T cells was multi-
plied by the volume of that organ (as determined by the weight
of that organ in comparably treated animals with the assumption
that 1 ml 
 
 
 
 1 cm
 
3
 
 
 
 
 
 1 gm) and divided by the average volume of
a T cell, as described previously (4).
 
Cell Isolation and Intracellular Staining for Detection of Cytokines.
 
BALB/c recipients of DO11.10 cells were injected subcutane-
ously in the tail with OVA peptide/IFA. 14 d later, mice were
challenged with an intravenous injection of 100 
 
 
 
g of OVA pep-
tide. Mice were killed 2 h later and inguinal, periaortic, and me-
senteric lymph nodes, and the tail injection sites were removed
and placed in chilled Eagles Hanks with amino acids medium
containing 10% FCS. Media for all subsequent steps were supple-
mented with 10 
 
 
 
g/ml of brefeldin A to inhibit secretion of in-
 
tracellular cytokine. Lymph nodes were mashed with the end of a
syringe plunger and incubated in PBS containing collagenase D
(Roche Applied Sciences; 400 U/ml), collagenase VII (Sigma-
Aldrich; 100 U/ml), or Liberase Blendzyme 3 (Roche Applied
Sciences) for 20 min at 37
 
 
 
C. The resulting cell suspension was
filtered to remove debris, washed with PBS, and placed in FCS-
containing medium on ice while the tail injection sites were pro-
cessed. Tail tissue was minced into small pieces and incubated for
15 min in the collagenase mixture at 37
 
 
 
C. The remaining frag-
ments were then mashed with the end of a syringe plunger and
incubated for an additional 15 min. The digested tissue was
minced an additional time before being passed through a filter to
obtain a single cell suspension. The suspension was then passed
over Lympholyte M (CedarLane Laboratories). Lymphocytes
were collected from the interface.
Lymph nodes cells and lymphocytes from the tail were fixed in
2% formaldehyde, permeabilized with 0.3% saponin, and stained
with fluorochrome-labeled anti-CD4, KJ1–26 or anti-Thy1.1,
and anti-IL-2 or IFN-
 
 
 
 antibodies to detect lymphokine produc-
tion in DO11.10 or OT-II T cells (36). Cells capable of binding
to CD62P were identified using a fusion protein containing the
extracellular portion of CD62P and the Fc portion of human IgG
(CD62P-Ig; BD Biosciences). CD62P-Ig was incubated with
cells for 30 min on ice. The cells were washed with PBS and
fixed in 2% formaldehyde. After fixation, cells were stained with
Cy5.5-labeled anti-CD4 and allophycocyanin-labeled KJ1–26
antibodies (Caltag) followed by PE-labeled goat anti-human IgG
antibody (Caltag). Human IgG (Caltag) was used as a negative
control for CD62P-Ig binding. Stained cells were analyzed by
flow cytometry.
 
Bromodeoxyuridine Labeling.
 
BALB/c recipients of DO11.10
cells were injected subcutaneously in the tail with 100 
 
 
 
g of
OVA peptide/IFA. At various times after immunization, mice
were injected intraperitoneally with 0.5 mg of bromodeoxyuri-
dine and then again 2 h later. Mice were killed 2 h after the sec-
ond bromodeoxyuridine injection and the inguinal, mesenteric,
and periaortic lymph nodes and tail injections sites were har-
vested. Cells were isolated as described for intracellular cytokine
staining. Isolated cells were stained with allophycocyanin-
labeled KJ1–26 antibody (Caltag) and Cy5.5-labeled anti-CD4
antibody (BD Biosciences) for 30 min on ice. Cells were washed
in PBS and suspended in 0.5 ml of 1% paraformaldehyde with
0.01% Tween 20, and stored overnight at 4
 
 
 
C. Cells were then
stained with FITC-labeled anti-bromodeoxyuridine antibody
(BD Biosciences) as described previously (37) and analyzed by
flow cytometry.
Bromodeoxyuridine incorporation was also assayed by immu-
nohistochemistry. The lungs, tail injection sites, and periaortic,
inguinal, and mesenteric lymph nodes were dissected from indi-
vidual mice that received OVA peptide/IFA and bromode-
oxyuridine as described above. Organs were frozen together in
O.C.T., sectioned, and stained with biotinylated-KJ1–26 anti-
body and tyramide-rhodamine from the TSA™-rhodamine kit
(NEN Life Science Products) according to manufacturer instruc-
tions. Sections were then washed briefly in PBS and incubated
an additional 60 min in 1% H
 
2
 
0
 
2
 
/0.01% azide. Slides were incu-
bated in avidin and biotin block (Vector Laboratories) before an-
tigen-retrieval according to the BD Biosciences bromodeoxyuri-
dine in situ detection kit (BD Biosciences). The sections were
then incubated with biotin-labeled anti-bromodeoxyuridine an-
tibody, washed with PBS, and incubated with Streptavidin-per-
oxidase for 30 min. After washing, slides were incubated for 5
min with biotinyl-tyramide (NEN Life Science Products),T
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washed, and incubated with streptavidin-Cy5 (Caltag) for 20
min. Slides were mounted with Vectashield (Vector Laborato-
ries). Digital images in the rhodamine, FITC, and Cy5 channels
were collected. The autofluorescence present on the FITC im-
ages was used to outline the anatomy of the tissue. Photoshop
5.5 software was used to color Rhodamine-stained objects red,
Cy5-stained objects green, and the FITC autofluorescence gray.
The three sets of images were then overlaid. DO11.10 T cells
that incorporated bromodeoxyuridine contained red and green
color and thus appeared yellow. Yellow objects significantly
smaller than an average cell were eliminated to ensure that yel-
low staining was due to true costaining rather then overlap of
green and red by two adjacent cells.
 
Results
 
Antigen-specific T Cells Accumulate at a Subcutaneous Site of
Antigen Deposition.
 
It was recently demonstrated that anti-
gen-specific CD4 T cells migrate to nonlymphoid organs
in large numbers after systemic exposure to antigen (4). Be-
cause the antigen had access to all parts of the body under
these conditions it was not possible to determine whether
or not the T cells migrated preferentially into antigen-con-
taining organs. This issue was addressed here by confining
antigen to a local site by injecting mice with OVA peptide/
IFA subcutaneously in the tail. This form of antigen ad-
ministration was chosen because IFA emulsions remain lo-
calized at the site of injection for weeks (38). To assess the
migration of antigen-specific CD4 T cells into this injec-
tion site it was necessary to transfer a small number of naive
OVA peptide-specific CD4 T cells from TCR transgenic
donor mice into normal mice before immunization because
the frequency of CD4 T cells specific for this peptide in the
normal T cell repertoire is below the limit of detection of
flow cytometry and immunohistology (39).
Whole-mouse immunohistology was used to determine
whether or not the local site of antigen injection was the
major nonlymphoid tissue into which antigen-specific
CD4 T cells migrated after subcutaneous immunization.
Sections prepared from normal B6 mice (Thy 1.2), or B6
mice that received several million OT-II TCR transgenic
CD4 T cells (Thy 1.1) were stained with Cy3-labeled anti-
Thy 1.1 antibody. A section through a normal mouse that
did not receive OT-II cells contained a few nonspecifi-
cally-stained objects, primarily in the kidney, muscle, and
liver (Fig. 1 A). As expected (4), a section through a recipi-
ent of OT-II cells that was not injected with OVA peptide
showed a similar appearance with the exception that
stained objects, presumably OT-II cells, were also present
in the spleen and lymph nodes (Fig. 1 B). No OT-II cells
were present in the tail tissue of naive mice (Fig. 1, B and
E), consistent with the theory that naive T cells circulate
through secondary lymphoid organs but not nonlymphoid
organs (40). As reported previously (4), OT-II cells were
detected at elevated levels in the spleen and several other
organs such as the liver, lung, salivary gland, intestines, and
thymus, 5 d after intravenous injection of OVA peptide
and LPS (Fig. 1 C). Very few OT-II cells migrated into the
tail under these conditions. In contrast, large numbers of
OT-II T cells were found in the tail tissue 5 d after subcu-
taneous injection of OVA peptide/IFA into this location
(Fig. 1, D and F).
A more quantitative immunohistochemical analysis was
performed using individual organs from BALB/c recipients
of DO11.10 RAG2-deficient CD4 T cells (Fig. 1 G). Na-
ive DO11.10 T cells were found in the spleen but not non-
lymphoid organs in mice that were not injected with OVA
peptide. The number of DO11.10 T cells in the spleen in-
creased 5 d after intravenous injection of OVA peptide plus
LPS or subcutaneous injection of OVA peptide/IFA.
DO11.10 T cells migrated into the lungs after both types of
antigen administration. In contrast, DO11.10 T cells mi-
grated to the intestines but not the tail after intravenous an-
tigen delivery, whereas DO11.10 cells entered the tail but
not the intestines after subcutaneous injection. The entry of
CD4 T cells into the tail appeared to be a function of the
route of antigen delivery and not the type of adjuvant used
since DO11.10 cells were found in the tail in similar num-
bers 5 d after subcutaneous priming with OVA peptide/
IFA or OVA peptide plus LPS (unpublished data). These
results show that although antigen-specific CD4 T cells en-
ter nonlymphoid organs after both systemic and localized
antigen administration, the distribution of T cells differs ac-
cording to the route of immunization.
 
Antigen-specific CD4 T Cells Accumulate Preferentially in the
Subcutaneous Antigen Injection Site.
 
It was possible that the
antigen-specific CD4 T cells that accumulated in the tail
injection site did so by sensing the inflamed blood vessels in
this location. It was also possible, that recognition of OVA
peptide–MHC II complexes played a role in this process.
To assess the roles of inflammation and antigen presenta-
tion, a small amount of IFA containing OVA peptide was
injected into one site on the tail, and an equal volume of
IFA alone was injected into another physically separate site
on the same tail. This created two inflamed sites that dif-
fered only by the presence or absence of antigen. The
number of transferred DO11.10 T cells was then deter-
mined in the tail-draining lymph nodes by flow cytometry
and at each tail injection site by immunohistochemistry.
Immunohistochemistry was used for tail tissue (on sections
of the type shown in Fig. 1 F) because only a small fraction
of the cells shown by immunohistochemistry to be in this
location could be released by enzymatic digestion for flow
cytometric analysis (unpublished data).
About 30,000 DO11.10 T cells were present in the
lymph nodes of recipients that were not injected with
OVA peptide (Fig. 2), or were injected with IFA alone
(unpublished data), whereas no cells were detected in the
tail tissue under these conditions (Fig. 2). The number of
DO11.10 T cells in the draining nodes increased 
 
 
 
10-fold
to 300,000 by day 5 after injection of OVA peptide/IFA
and IFA in separate sites on the same tail, and then de-
creased progressively over the next several weeks. Small
numbers of DO11.10 T cells first appeared in the OVA
peptide/IFA and IFA injection sites by day 3. The number
of DO11.10 T cells in the OVA peptide/IFA injection sites
then increased 300-fold to a peak of 1,000,000 on day 14.T
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Figure 1. Detection of antigen-specific T cells in whole body sections following different routes of immunization. Images from anti-Thy 1.1/Cy3-
stained sections through the following mice are shown: (A) a normal B6 mouse that did not receive OT-II cells; (B) a B6 mouse that received 3   106
OT-II cells intravenously 5 d before sacrifice; (C) a B6 mouse that received OT-II cells, was injected intravenously the next day with 100  g OVA pep-
tide and 25  g LPS, and was killed 4 d later; and (D) a B6 mouse that received OT-II cells, was injected subcutaneously in the tail with 100  g OVA
peptide/IFA and was killed 4 d later. B, brain; H, heart; K, kidney; L, lung; C, colon; Lv, liver; M, muscle; S, spleen; Sa, salivary glands; Si, small intes-
tine; T, thymus; Ts, testes; Ta, Tail; *, lymph nodes. Enlarged cross sections KJ1-stained through normal tail tissue (E) or a day 5 tail site containing OVA
peptide/IFA (F) from recipients of DO11.10 T cells are also shown. The number of DO11.10 T cells (assessed in spleens by flow cytometry and in the
other organs by immunohistology) present on day 5 in the indicated organs in mice injected with 100  g OVA peptide and 25  g LPS intravenously
(white bars), 100  g OVA peptide/IFA subcutaneously (black bars), or nothing (shaded bars) is shown in G.T
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During this period, the number of DO11.10 cells in the
IFA injection site increased to a peak of 30,000. The num-
ber of DO11.10 cells in the tail tissue sites then fell sharply
between days 14 and 20 and slowly thereafter to the limit
of detection by day 60. Therefore, antigen-specific CD4 T
cells migrated into normal and inflamed tissue that did not
contain antigen, but only accumulated to large numbers in
inflamed tissue containing antigen.
 
Antigen-specific CD4 T Cells Do Not Proliferate after Enter-
ing the Antigen Injection Site.
 
As no antigen-specific CD4 T
cells were found in the tail before immunization (Fig. 1, B,
E, and G), their initial appearance at this site must have been
due to migration from some other part of the body. How-
ever, it was possible that the dramatic increase in cell num-
ber seen in the antigen injection site between days 3 and 14
(Fig. 2) was due to the proliferation of the initial immigrants.
To address this question, the thymidine analogue bro-
modeoxyuridine was used to label cells undergoing prolif-
eration during the time that the antigen-specific T cells ac-
cumulated at the injection site. Recipients of DO11.10 T
cells were exposed to bromodeoxyuridine for 4 h at various
times after subcutaneous injection of OVA peptide/IFA.
This short pulse was used to maximize the chance that cells
incorporated bromodeoxyuridine in the location in which
they were sampled. The transferred cells were identified by
coexpression of CD4 and the clonotypic TCR (Fig. 3 A).
20–50% of the DO11.10 T cells in the draining lymph
nodes were labeled with a 4 h pulse of bromodeoxyuridine
3 d after injection of OVA peptide/IFA (Fig. 3, B and C).
This labeling pattern was consistent with an earlier study
(39), which showed that many DO11.10 T cells in the
draining lymph nodes are in the cell cycle at this time. The
fraction of bromodeoxyuridine-labeled DO11.10 T cells in
the draining lymph nodes declined on days 5 and 7 al-
though an easily detectable population was still present
(Figs. 3 C and 4 A). The DO11.10 T cells in the nondrain-
Figure 2. Quantification of antigen-specific CD4 T cells after subcutane-
ous injection of antigen. Mice were injected at two sites on the tail: one site
with OVA peptide/IFA, and the second site with IFA alone. The graph
shows the number of DO11.10 RAG2-deficient cells   SEM (n   2–3
mice per timepoint in three independent experiments) found in the drain-
ing inguinal and periaortic lymph nodes (squares), the injection site contain-
ing OVA peptide/IFA (circles), or the injection site containing IFA alone
(triangles). The minimum value for the Y axis is the limit of detection.
Figure 3. In vivo proliferation by antigen-specific CD4 T cells. Recip-
ients of naive DO11.10 T cells were injected with OVA peptide/IFA. 3
or 7 d later, mice were injected with bromodeoxyuridine over a 4 h pe-
riod immediately preceding sacrifice, and intracellular staining was used to
detect bromodeoxyuridine incorporation in DO11.10 T cells. The gate
used to identify DO11.10 cells is shown in panel A for draining lymph
nodes (DLN) and tail tissue from mice injected with OVA peptide/IFA
7 d earlier. Staining with anti-bromodeoxyuridine (filled histograms) or
an isotype control antibody (open histograms) in DO11.10 cells isolated
from the draining inguinal and periaoritic lymph nodes (DLN), nondrain-
ing mesenteric lymph nodes (NDLN), or tail injection sites, 3 or 7 d after
immunization is shown in B. C shows the mean percentage of DO11.10
T cells   SEM (n   5–7 mice per time point from two independent ex-
periments) that incorporated bromodeoxyuridine in the draining lymph
nodes (black bars), nondraining lymph nodes (gray bars), or tail injection
sites (white bars).T
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ing lymph nodes were not labeled with bromodeoxyuri-
dine (Fig. 3, B and C, and Fig. 4 B), demonstrating the
local nature of this immune response. Surprisingly, bro-
modeoxyuridine-labeled DO11.10 T cells were not de-
tected in the antigen injection site on days 3, 5, or 7 (Figs.
3 C and 4 C), despite the fact that the number of DO11.10
T cells in this location increased dramatically during this
period (Fig. 2). Immunohistochemical analysis of tail sec-
tions from these mice showed the presence of bromode-
oxyuridine-labeled cells other than DO11.10 T cells,
demonstrating that cells in this location had access to bro-
modeoxyuridine during the 4 h treatment period (Fig. 4
C). These results showed that antigen-specific CD4 T cells
did not proliferate extensively after entering the nonlym-
phoid site of antigen deposition. Therefore, immigration
from another part of the body was a more likely explana-
tion for the accumulation of these cells.
 
CD62P-binding, Antigen-specific CD4 T Cells Appear in the
Draining Lymph Nodes and then Accumulate at the Antigen In-
jection Site.
 
Because the DO11.10 T cells showed no signs
of division after entering the antigen injection site it was
possible that these cells had never divided. However, since
it is thought that only antigen-experienced T cells are capa-
ble of migrating into nonlymphoid tissues (40, 41), it
seemed more likely that the DO11.10 cells divided else-
where before migrating. These possibilities were addressed
by labeling the naive DO11.10 T cells with CFSE before
transfer and measuring cell division-related dilution of the
dye (42). Because cell division history correlated with
CD62P binding by lymph node T cells in another study
(43), the cells were also tested for CD62P-binding activity
using CD62P-Ig (44).
The DO11.10 T cells in the lymph nodes at the time of
OVA peptide/IFA injection contained high levels of CFSE
(Fig. 5) and did not bind CD62P as expected for naive T
cells (11, 43). By 2 d after injection, most of the DO11.10
T cells in the draining lymph nodes had divided at least
once, with many of the cells showing signs of multiple cell
divisions. At this time, a subset of the most divided cells in
the draining lymph nodes bound CD62P. DO11.10 T cells
could not be isolated from the injection site 2 d after anti-
gen injection (unpublished data). The DO11.10 T cells
continued to divide in the draining lymph nodes such that
by day 5 many of the cells had divided more than six times.
Again, a subset of the most divided cells bound CD62P. By
this time, DO11.10 T cells could be isolated from the tail
injection site. All of these cells had divided more than 6
times and most bound CD62P. Thus, the most divided cells
in the lymph node resembled the cells in the tail with re-
spect to CD62P-binding activity. The CFSE staining pat-
tern for DO11.10 T cells in the draining lymph nodes did
not change between days 5 and 11, indicating that cell divi-
sion ceased during this interval. By day 11, very few
CD62P-binding DO11.10 T cells remained in the draining
lymph nodes. In contrast, all of the DO11.10 T cells at the
injection site at this time bound CD62P. Together these re-
sults are consistent with a scenario in which antigen-specific
CD4 T cells are stimulated in the draining lymph nodes. A
subset of these cells, which divides more than other cells in
the population, acquires the ability to bind CD62P, leaves
the lymph nodes, and migrates to the injection site.
Figure 4. In situ detection of bromodeoxyuridine-labeled cells. Recip-
ients of naive DO11.10 T cells were injected with OVA peptide/IFA. 7 d
later mice were either injected with bromodeoxyuridine over a 4 h pe-
riod just before sacrifice (A–C), or did not receive bromodeoxyuridine
(D). Sections of a draining inguinal lymph node (A), a nondraining me-
senteric lymph node (B), or tail (C and D) stained with KJ1–26 (Cy3,
red), and anti-bromodeoxyuridine (Cy5, green) antibodies are shown.
The tail section shown in D served as a control for false double-positive
staining. The number in the upper left corner of each panel represents the
percentage of red KJ1–26  cells that also stained green with anti-bro-
modeoxyuridine antibody, and thus appear as yellow objects.
Figure 5. The most divided antigen-specific CD4 T cells in the lymph
nodes and antigen injection site bind CD62P. The dot plots show the
levels of CD62P binding and CFSE dilution in KJ1–26  cells from the
draining lymph nodes or tails of BALB/c recipients of CFSE labeled
DO11.10 T cells that were injected subcutaneously in the tail with OVA
peptide/IFA.T
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Migration of Antigen-specific CD4 T Cells to a Site of Antigen Deposition
 
CD62E Is Critical for the Entry of Antigen-specific CD4 T
Cells into the Antigen Injection Site.
 
Because CD62P-bind-
ing antigen-specific CD4 T cells accumulated at the anti-
gen injection site and because most T cells that bind
CD62P also bind CD62E (16), it was possible that these
molecules played a role in the migration process. This pos-
sibility was tested by assessing the capacity of antigen-spe-
cific CD4 T cells to accumulate at the site of antigen injec-
tion in mice lacking CD62P, CD62E, or both CD62P and
CD62E. The adoptive transfer of OT-II cells was used for
this purpose because the selectin-deficient recipients were
on the B6 background.
The accumulation of OT-II cells in the draining lymph
nodes 5 d after subcutaneous injection of OVA peptide/
IFA was similar in normal and CD62P-deficient mice (Fig.
6 A). In addition, similar numbers of OT-II cells were
present in the tail injection sites in both groups. In contrast,
OT-II T cells accumulated in the antigen injection sites of
mice lacking CD62E (Fig. 6 B) or CD62P and CD62E
(Fig. 6 C) 6–10-fold less well than they did in normal mice.
The draining lymph nodes of CD62E-deficient or
CD62E/P-deficient recipients of OT-II cells also con-
tained one half to one third as many OT-II cells as the
draining lymph nodes of normal mice, 5 d after OVA/IFA
injection. Although this difference could have been ex-
plained by the fact that about half as many OT-II cells were
present in the lymph nodes of CD62E/P-deficient mice
before immunization, this could not account of the differ-
ence in CD62E-deficient mice, which contained the same
number of OT-II cells in the lymph nodes as normal mice
before antigen injection. These results indicated that the
CD62E expression by the recipient was critical for maximal
accumulation of antigen-specific CD4 T cells in the drain-
ing lymph nodes and site of antigen injection.
 
Antigen-specific CD4 T Cells at the Antigen Injection Site
Produce IFN-
 
 
 
 but Not IL-2.
 
The preferential accumula-
tion of antigen-specific CD4 T cells in the antigen injec-
tion sites several weeks after immunization raised the possi-
bility that these T cells recognized peptide–MHC II
complexes in this location. This possibility was explored
using a method that allows direct ex vivo detection of in-
tracellular IL-2 and IFN-
 
 
 
 in transferred DO11.10 cells
(36). About 15% of the DO11.10 cells in the tail injection
sites on day 14 contained IFN-
 
 
 
, a value that increased to
30% (Fig. 7 B) after challenge with OVA peptide. In con-
trast, very few of the DO11.10 cells in the tail injection
sites on day 14 contained IL-2 before or after challenge
(Fig. 7, A and B), perhaps explaining why these cells did
not proliferate in the injection site. The DO11.10 cells in
the draining lymph nodes of mice injected with OVA pep-
tide/IFA 14 d earlier did not contain IL-2 or IFN-
 
 
 
 (Fig.
7, A and B), but 
 
 
 
10% of the cells produced IL-2 but not
IFN-
 
 
 
, 2 h after challenge with OVA peptide (Fig. 7, A
and B). The presence of IFN-
 
 
 
 in the antigen-specific
CD4 T cells that resided in the antigen injection site is evi-
dence that these cell were undergoing active stimulation in
this location, despite a lack of IL-2 production and prolifer-
ation. In contrast, the antigen-experienced CD4 T cells
that resided in the lymph nodes showed no signs of consti-
tutive stimulation and produced IL-2 but not IFN-
 
 
 
 when
challenged with antigen.
 
Discussion
 
The results presented here provide clear evidence that
the local site of antigen deposition is the major nonlym-
phoid tissue in which activated antigen-specific CD4 T
cells accumulate during the primary response. This con-
clusion is supported by the recent finding that antigen-
specific CD4 T cells accumulate in the lungs after nasal
influenza virus infection (7). These studies imply that pep-
tide–MHC II recognition plays a role in either the migra-
Figure 6. Antigen-specific CD4 T cells do
not migrate to the subcutaneous antigen injec-
tion site in the absence of CD62E. Thy 1.1 
OT-II T cells were transferred into normal,
CD62P-deficient, CD62E-deficient, or
CD62E/P-deficient mice, some of which were
then injected subcutaneously in the tail with
100  g of OVA peptide/IFA. The mean num-
ber   SEM (n   4–6 mice) of OT-II T cells
detected in the draining periaortic and inguinal
lymph nodes (by flow cytometry) or tail injec-
tion sites (by immunohistology) of normal or CD62-deficient mice 5 d after OVA peptide/IFA injection are shown. Normal recipients (black bars) were
compared with CD62P-deficient (A), CD62E-deficient (B), or CD62E/P-deficient recipients (white bars) in separate experiments.
Figure 7. IL-2 and IFN-  production by antigen-specific CD4 T cells.
Recipients of naive DO11.10 T cells were injected with OVA peptide/
IFA. 14 d later, ex vivo intracellular staining was used to detect IL-2 (A)
or IFN-  (B) in DO11.10 T cells before (black bars) or 2 h after intrave-
nous injection of 100  g of OVA peptide (white bars).T
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tion or retention of antigen-specific T cells in non-
lymphoid tissues. It is therefore likely, that the previously
reported migration of antigen-specific T cells into most
nonlymphoid tissues after systemic antigen administration
(4, 30, 45) is explained in part by the body-wide distribu-
tion of antigen in this situation. However, the fact that
some antigen-specific CD4 T cells accumulated in the
lungs and thymus after subcutaneous injection of antigen
suggests that local antigen presentation is not the only fac-
tor that determines the distribution of antigen-specific T
cells in certain nonlymphoid tissues.
It is currently thought that the migration of activated T
cells into nonlymphoid organs is controlled by induction of
homing and chemokine receptors on the T cells and in-
flammation-dependent display of selectins, adhesion mole-
cules, and chemokines on blood vessels (8, 46). It was re-
cently shown that the induction of homing molecules on
the T cells is influenced by the type of secondary lymphoid
organ in which peptide–MHC II recognition occurs. For
example, several days after systemic administration of anti-
gen, antigen-specific CD62P-binding CD4 T cells lacking
 
 
 
4
 
 
 
7 integrin were generated in peripheral lymph nodes,
whereas cells expressing high levels of 
 
 
 
4
 
 
 
7 integrin but
lacking CD62P-binding activity were generated in mucosal
lymph nodes (43). As inflamed blood vessels in the skin and
mucosal tissues express CD62P and CD62E (47–49) or
MadCAM-1 (50), respectively, it was possible that the
CD62P-binding T cells generated in peripheral lymph
nodes, migrated to the skin, whereas the 
 
 
 
4 7 integrin-
expressing T cells in the mucosal lymphoid organs migrated
to the mucosal tissues. Our findings that CD62P-binding
antigen-specific CD4 T cells were generated in the drain-
ing lymph nodes early after subcutaneous antigen injection
and then accumulated at the injection site is consistent with
this scenario.
The finding that CD62E is critical for the migration of
antigen-experienced CD4 T cells to the site of antigen
deposition during the primary response is consistent with
earlier reports that secondary T cell responses in the skin
are dependent on CD62E and/or CD62P expression on
blood vessels (17–19, 21, 23, 24, 51). CD62E has been re-
ported to play a larger role than CD62P in the migration of
polyclonal T cells into a skin site injected with inflamma-
tory cytokines and the migration of porcine T cells into the
skin during the DTH reaction (23, 52). In our experi-
ments, antigen-experienced CD4 T cells used CD62E
preferentially to enter the injection site while retaining the
ability to bind to CD62P. This situation could be related to
temporal differences in the expression of CD62E and
CD62P. For example, CD62E may be expressed on skin
blood vessels at higher levels than CD62P several days after
immunization when antigen-experienced T cells are leav-
ing the lymph nodes and entering the bloodstream. It is
currently not clear which receptor is used by the antigen-
experienced T cells to recognize CD62E and enter the in-
jection site. Although PSGL-1 and CD62E ligand-1 are
both candidates, we favor PSGL-1 because it is expressed
by T cells at the injection site and can account for the fact
that they bind CD62P and CD62E.
At first glance it was surprising to find that antigen-spe-
cific CD4 T cells did not accumulate normally in the drain-
ing lymph nodes of recipients lacking CD62E. As CD62E
is not expressed on T cells or APCs (53) it is unlikely that it
could directly influence T cell activation or proliferation.
Therefore, we favor the idea that the reduced accumula-
tion in the lymph nodes was a secondary effect of the re-
duced accumulation of T cells at the injection site. As acti-
vated T cells can enter lymph nodes from tissues via
afferent lymphatic vessels (41), the number of antigen-spe-
cific T cells in the draining lymph nodes after immuniza-
tion is determined by two inputs: cells that proliferated and
remained in the lymph node and cells that migrated to the
injection site and reentered the lymph node via the afferent
lymph. In the absence of CD62E, this second source of T
cells would be missing, resulting in fewer T cells in the
draining lymph nodes.
As mouse endothelial cells can express MHC II mole-
cules under certain conditions (54, 55), it is possible that
recognition of peptide–MHC II complexes on blood ves-
sels played a role in the entry of antigen-specific CD4 T
cells into the antigen injection site. However, the fact that
the antigen-specific CD4 T cells initially entered equally
into sites containing antigen plus IFA or IFA alone suggests
that an antigen-independent mechanism is involved in en-
try. Thus, it is more likely that the antigen-specific T cells
initially passed out of blood vessels at both types of injec-
tion sites by recognizing CD62E and other adhesive
ligands. The much greater subsequent accumulation of an-
tigen-specific T cells in the antigen-containing sites could
then have occurred because the T cells were retained in
this location as a consequence of peptide–MHC II recogni-
tion on local APC. Support for this scenario comes from
earlier experiments in which adoptively transferred neu-
roantigen- or OVA-specific T cell clones entered the brain
equally, but only the neuroantigen-specific cells accumu-
lated in this location (56). Similarly, although activated
CD8 T cells enter many inflamed tissues, they accumulate
in tissues containing in antigen (57, 58).
Remarkably, the accumulation of antigen-specific CD4
T cells at subcutaneous sites of antigen injection was not as-
sociated with proliferation in this location. This lack of
proliferation was not due to a lack of peptide–MHC II rec-
ognition because a sizeable fraction of the T cells in this site
at 2 wk were producing IFN-  constitutively. A similar
state where proliferative capacity is lost but effector func-
tion is retained has been described recently for activated
CD8 T cells (59, 60) and IL-4–producing T cells in the
lungs (6). Despite the lack of proliferation at the injection
site, the antigen-specific CD4 T cells had divided on aver-
age more than the cells in the lymph nodes at the same
time. This could be explained by the fact that the T cells
divided extensively in the lymph nodes before migrating to
the injection site. The most divided T cells may have accu-
mulated preferentially at the injection site because theseT
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were the only cells in the lymph nodes that acquired the
ability to bind CD62E.
Coordinate regulation of homing molecule expression
and lymphokine production potential by cell division may
also explain the observation that IFN- –producing T cells
resided preferentially at the injection site, whereas IL-2–
producing cells resided preferentially in lymph nodes. In
vitro experiments have shown that multiple cell divisions
favor acquisition of the capacity to produce effector lym-
phokines such as IL-4 and IFN-  (61), although this was
not the case in at least one in vivo situation (62). There-
fore, it is possible that the CD4 T cells that divide the
most in the lymph nodes acquire the capacity to produce
effector lymphokines and express homing molecules
needed to enter nonlymphoid organs. In the case of an in-
fection, this sequence of events would produce the desir-
able result of concentrating CD4 T cells with the capacity
to produce anti-microbial lymphokines at the nonlym-
phoid infection site.
We thank Jennifer Walter for technical assistance.
This work was supported by National Institutes of Health re-
search grants AI27998, AI35296, AI39614 (M.K. Jenkins), AI35783
(C.T. Weaver), AR46404 (D.C. Bullard), and National Institutes
of Health training grant AI07313 (R.L. Reinhardt).
Submitted: 25 September 2002
Revised: 12 December 2002
Accepted: 27 January 2003
References
1. von Andrian, U.H., and C.R. Mackay. 2000. T-cell function
and migration. N. Engl. J. Med. 343:1020–1034.
2. Banchereau, J., and R.M. Steinman. 1998. Dendritic cells
and the control of immunity. Nature. 392:245–252.
3. Jenkins, M.K., A. Khoruts, E. Ingulli, D.L. Mueller, S.J. Mc-
Sorley, R.L. Reinhardt, A. Itano, and K.A. Pape. 2001. In
vivo activation of antigen-specific CD4 T cells. Annu. Rev.
Immunol. 19:23–45.
4. Reinhardt, R.L., A. Khoruts, R. Merica, T. Zell, and M.K.
Jenkins. 2001. Visualizing the generation of memory CD4 T
cells in the whole body. Nature. 410:101–105.
5. Mohrs, M., K. Shinkai, K. Mohrs, and R.M. Locksley. 2001.
Analysis of type 2 immunity in vivo with a bicistronic IL-4
reporter. Immunity. 15:303–311.
6. Harris, N.L., V. Watt, F. Ronchese, and G. Le Gros. 2002.
Differential T cell function and fate in lymph node and non-
lymphoid tissues. J. Exp. Med. 195:317–326.
7. Roman, E., E. Miller, A. Harmsen, J. Wiley, U.H. Von An-
drian, G. Huston, and S.L. Swain. 2002. CD4 effector T cell
subsets in the response to influenza: heterogeneity, migration,
and function. J. Exp. Med. 196:957–968.
8. Campbell, J.J., and E.C. Butcher. 2000. Chemokines in
tissue-specific and microenvironment-specific lymphocyte
homing. Curr. Opin. Immunol. 12:336–341.
9. Fuhlbrigge, R.C., J.D. Kieffer, D. Armerding, and T.S. Kup-
per. 1997. Cutaneous lymphocyte antigen is a specialized
form of PSGL-1 expressed on skin-homing T cells. Nature.
389:978–981.
10. Steegmaier, M., A. Levinovitz, S. Isenmann, E. Borges, M.
Lenter, H.P. Kocher, B. Kleuser, and D. Vestweber. 1995.
The E-selectin-ligand ESL-1 is a variant of a receptor for fi-
broblast growth factor. Nature. 373:615–620.
11. Lim, Y.C., L. Henault, A.J. Wagers, G.S. Kansas, F.W. Lus-
cinskas, and A.H. Lichtman. 1999. Expression of functional
selectin ligands on Th cells is differentially regulated by IL-12
and IL-4. J. Immunol. 162:3193–3201.
12. Maly, P., A. Thall, B. Petryniak, C.E. Rogers, P.L. Smith,
R.M. Marks, R.J. Kelly, K.M. Gersten, G. Cheng, T.L.
Saunders, et al. 1996. The alpha(1,3) fucosyltransferase Fuc-
TVII controls leukocyte trafficking through an essential role
in L-, E-, and P-selectin ligand biosynthesis. Cell. 86:643–
653.
13. Blander, J.M., I. Visintin, C.A. Janeway, Jr., and R. Medzhi-
tov. 1999. Alpha(1,3)-fucosyltransferase VII and alpha(2,3)-
sialyltransferase IV are up-regulated in activated CD4 T cells
and maintained after their differentiation into Th1 and migra-
tion into inflammatory sites. J. Immunol. 163:3746–3752.
14. Lim, Y.C., H. Xie, C.E. Come, S.I. Alexander, M.J. Grusby,
A.H. Lichtman, and F.W. Luscinskas. 2001. IL-12, STAT4-
dependent up-regulation of CD4( ) T cell core 2 beta-1,6-
n-acetylglucosaminyltransferase, an enzyme essential for bio-
synthesis of P-selectin ligands. J. Immunol. 167:4476–4484.
15. White, S.J., G.H. Underhill, M.H. Kaplan, and G.S. Kansas.
2001. Differential requirements for Stat4 in expression of gly-
cosyltransferases responsible for selectin ligand formation in
Th1 cells. J. Immunol. 167:628–631.
16. Tietz, W., Y. Allemand, E. Borges, D. von Laer, R. Hall-
mann, D. Vestweber, and A. Hamann. 1998. CD4  T cells
migrate into inflamed skin only if they express ligands for E-
and P-selectin. J. Immunol. 161:963–970.
17. Austrup, F., D. Vestweber, E. Borges, M. Lohning, R.
Brauer, U. Herz, H. Renz, R. Hallmann, A. Scheffold, A.
Radbruch, and A. Hamann. 1997. P- and E-selectin mediate
recruitment of T-helper-1 but not T-helper-2 cells into in-
flamed tissues. Nature. 385:81–83.
18. Hirata, T., G. Merrill-Skoloff, M. Aab, J. Yang, B.C. Furie,
and B. Furie. 2000. P-Selectin glycoprotein ligand 1
(PSGL-1) is a physiological ligand for E-selectin in mediating
T helper 1 lymphocyte migration. J. Exp. Med. 192:1669–
1676.
19. Subramaniam, M., S. Saffaripour, S.R. Watson, T.N. Maya-
das, R.O. Hynes, and D.D. Wagner. 1995. Reduced recruit-
ment of inflammatory cells in a contact hypersensitivity
response in P-selectin-deficient mice. J. Exp. Med. 181:
2277–2282.
20. Labow, M.A., C.R. Norton, J.M. Rumberger, K.M. Lom-
bard-Gillooly, D.J. Shuster, J. Hubbard, R. Bertko, P.A.
Knaack, R.W. Terry, and M.L. Harbison. 1994. Character-
ization of E-selectin-deficient mice: demonstration of over-
lapping function of the endothelial selectins. Immunity.
1:709–720.
21. Staite, N.D., J.M. Justen, L.M. Sly, A.L. Beaudet, and D.C.
Bullard. 1996. Inhibition of delayed-type contact hypersensi-
tivity in mice deficient in both E-selectin and P-selectin.
Blood. 88:2973–2979.
22. Erdmann, I., E.P. Scheidegger, F.K. Koch, L. Heinzerling, B.
Odermatt, G. Burg, J.B. Lowe, and T.M. Kundig. 2002. Fu-
cosyltransferase VII-deficient mice with defective E-, P-, and
L-selectin ligands show impaired CD4  and CD8  T cell
migration into the skin, but normal extravasation into visceral
organs. J. Immunol. 168:2139–2146.
23. Binns, R.M., A. Whyte, S.T. Licence, A.A. Harrison, Y.T.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
761 Reinhardt et al.
Tsang, D.O. Haskard, and M.K. Robinson. 1996. The role
of E-selectin in lymphocyte and polymorphonuclear cell re-
cruitment into cutaneous delayed hypersensitivity reactions in
sensitized pigs. J. Immunol. 157:4094–4099.
24. Silber, A., W. Newman, V.G. Sasseville, D. Pauley, D. Beall,
D.G. Walsh, and D.J. Ringler. 1994. Recruitment of lym-
phocytes during cutaneous delayed hypersensitivity in non-
human primates is dependent on E-selectin and vascular cell
adhesion molecule 1. J. Clin. Invest. 93:1554–1563.
25. Campbell, D.J., C.H. Kim, and E.C. Butcher. 2001. Separa-
ble effector T cell populations specialized for B cell help or
tissue inflammation. Nat. Immunol. 2:876–881.
26. Picker, L.J., L.W. Terstappen, L.S. Rott, P.R. Streeter, H.
Stein, and E.C. Butcher. 1990. Differential expression of
homing-associated adhesion molecules by T cell subsets in
man. J. Immunol. 145:3247–3255.
27. Topham, D.J., M.R. Castrucci, F.S. Wingo, G.T. Belz, and
P.C. Doherty. 2001. The role of antigen in the localization of
naive, acutely activated, and memory CD8( ) T cells to the
lung during influenza pneumonia. J. Immunol. 167:6983–
6990.
28. Cross, A.H., T. O’Mara, and C.S. Raine. 1993. Chronologic
localization of myelin-reactive cells in the lesions of relapsing
EAE: implications for the study of multiple sclerosis. Neurol-
ogy. 43:1028–1033.
29. Liu, C.P., K. Jiang, C.H. Wu, W.H. Lee, and W.J. Lin.
2000. Detection of glutamic acid decarboxylase-activated T
cells with I-Ag7 tetramers. Proc. Natl. Acad. Sci. USA. 97:
14596–14601.
30. Masopust, D., V. Vezys, A.L. Marzo, and L. Lefrancois.
2001. Preferential localization of effector memory cells in
nonlymphoid tissue. Science. 291:2413–2417.
31. Murphy, K.M., A.B. Heimberger, and D.Y. Loh. 1990.
Induction by antigen of intrathymic apoptosis of CD4 
CD8 TCRlo thymocytes in vivo. Science. 250:1720–
1723.
32. Barnden, M.J., J. Allison, W.R. Heath, and F.R. Carbone.
1998. Defective TCR expression in transgenic mice con-
structed using cDNA-based alpha- and beta-chain genes un-
der the control of heterologous regulatory elements. Immunol.
Cell Biol. 76:34–40.
33. Bullard, D.C., E.J. Kunkel, H. Kubo, M.J. Hicks, I. Lorenzo,
N.A. Doyle, C.M. Doerschuk, K. Ley, and A.L. Beaudet.
1996. Infectious susceptibility and severe deficiency of leuko-
cyte rolling and recruitment in E-selectin and P-selectin dou-
ble mutant mice. J. Exp. Med. 183:2329–2336.
34. Haskins, K., R. Kubo, J. White, M. Pigeon, J. Kappler, and
P. Marrack. 1983. The major histocompatibility complex-
restricted antigen receptor on T cells. I. Isolation with a
monoclonal antibody. J. Exp. Med. 157:1149–1169.
35. Southern, P.J., P. Blount, and M.B. Oldstone. 1984. Analysis
of persistent virus infections by in situ hybridization to
whole-mouse sections. Nature. 312:555–558.
36. Khoruts, A., A. Mondino, K.A. Pape, S.L. Reiner, and M.K.
Jenkins. 1998. A natural immunological adjuvant enhances T
cell clonal expansion through a CD28-dependent, interleu-
kin (IL)-2-independent mechanism. J. Exp. Med. 187:225–
236.
37. Penit, C., and F. Vasseur. 1997. Expansion of mature thy-
mocyte subsets before emigration to the periphery. J. Immu-
nol. 159:4848–4856.
38. Warren, H.S., F.R. Vogel, and L.A. Chedid. 1986. Current
status of immunological adjuvants. Annu. Rev. Immunol.
4:369–388.
39. Kearney, E.R., K.A. Pape, D.Y. Loh, and M.K. Jenkins.
1994. Visualization of peptide-specific T cell immunity and
peripheral tolerance induction in vivo. Immunity. 1:327–339.
40. Mackay, C.R., D.P. Andrew, M. Briskin, D.J. Ringler, and
E.C. Butcher. 1996. Phenotype, and migration properties of
three major subsets of tissue homing T cells in sheep. Eur. J.
Immunol. 26:2433–2439.
41. Mackay, C., W. Marston, and L. Dudler. 1990. Naive and
memory T cells show distinct pathways of lymphocyte recir-
culation. J. Exp. Med. 171:801–817.
42. Lyons, A.B., and C.R. Parish. 1994. Determination of lym-
phocyte division by flow cytometry. J. Immunol. Methods.
171:131–137.
43. Campbell, D.J., and E.C. Butcher. 2002. Rapid acquisition
of tissue-specific homing phenotypes by CD4( ) T cells ac-
tivated in cutaneous or mucosal lymphoid tissues. J. Exp.
Med. 195:135–141.
44. Todderud, G., J. Alford, K.A. Millsap, A. Aruffo, and K.M.
Tramposch. 1992. PMN binding to P-selectin is inhibited by
sulfatide. J. Leukoc. Biol. 52:85–88.
45. Marshall, D.R., S.J. Turner, G.T. Belz, S. Wingo, S. An-
dreansky, M.Y. Sangster, J.M. Riberdy, T. Liu, M. Tan, and
P.C. Doherty. 2001. Measuring the diaspora for virus-spe-
cific CD8  T cells. Proc. Natl. Acad. Sci. USA. 98:6313–
6318.
46. Moser, B., and P. Loetscher. 2001. Lymphocyte traffic con-
trol by chemokines. Nat. Immunol. 2:123–128.
47. Geng, J.G., M.P. Bevilacqua, K.L. Moore, T.M. McIntyre,
S.M. Prescott, J.M. Kim, G.A. Bliss, G.A. Zimmerman, and
R.P. McEver. 1990. Rapid neutrophil adhesion to activated
endothelium mediated by GMP-140. Nature. 343:757–760.
48. Groves, R.W., M.H. Allen, J.N. Barker, D.O. Haskard, and
D.M. MacDonald. 1991. Endothelial leucocyte adhesion
molecule-1 (ELAM-1) expression in cutaneous inflamma-
tion. Br. J. Dermatol. 124:117–123.
49. Silber, A., W. Newman, K.A. Reimann, E. Hendricks, D.
Walsh, and D.J. Ringler. 1994. Kinetic expression of endo-
thelial adhesion molecules and relationship to leukocyte re-
cruitment in two cutaneous models of inflammation. Lab. In-
vest. 70:163–175.
50. Streeter, P.R., E.L. Berg, B.T. Rouse, R.F. Bargatze, and
E.C. Butcher. 1988. A tissue-specific endothelial cell mole-
cule involved in lymphocyte homing. Nature. 331:41–46.
51. Hirata, T., B.C. Furie, and B. Furie. 2002. P-, E-, and
L-selectin mediate migration of activated CD8  T lympho-
cytes into inflamed skin. J. Immunol. 169:4307–4313.
52. Kulidjian, A.A., A.C. Issekutz, and T.B. Issekutz. 2002. Dif-
ferential role of E-selectin and P-selectin in T lymphocyte
migration to cutaneous inflammatory reactions induced by
cytokines. Int. Immunol. 14:751–760.
53. Bevilacqua, M.P., S. Stengelin, M.A. Gimbrone, Jr., and B.
Seed. 1989. Endothelial leukocyte adhesion molecule 1: an
inducible receptor for neutrophils related to complement
regulatory proteins and lectins. Science. 243:1160–1165.
54. St Louis, J.D., J.A. Lederer, and A.H. Lichtman. 1993. Co-
stimulator deficient antigen presentation by an endothelial
cell line induces a nonproliferative T cell activation response
without anergy. J. Exp. Med. 178:1597–1605.
55. Girvin, A.M., K.B. Gordon, C.J. Welsh, N.A. Clipstone, and
S.D. Miller. 2002. Differential abilities of central nervous sys-
tem resident endothelial cells and astrocytes to serve as induc-
ible antigen-presenting cells. Blood. 99:3692–3701.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
762 Migration of Antigen-specific CD4 T Cells to a Site of Antigen Deposition
56. Zeine, R., and T. Owens. 1992. Direct demonstration of the
infiltration of murine central nervous system by Pgp-1/
CD44high CD45RB(low) CD4  T cells that induce experi-
mental allergic encephalomyelitis. J. Neuroimmunol. 40:57–69.
57. Masopust, D., J. Jiang, H. Shen, and L. Lefrancois. 2001. Di-
rect analysis of the dynamics of the intestinal mucosa CD8 T
cell response to systemic virus infection. J. Immunol. 166:
2348–2356.
58. Hogan, R.J., E.J. Usherwood, W. Zhong, A.A. Roberts,
R.W. Dutton, A.G. Harmsen, and D.L. Woodland. 2001.
Activated antigen-specific CD8  T cells persist in the lungs
following recovery from respiratory virus infections. J. Immu-
nol. 166:1813–1822.
59. Deeths, M.J., R.M. Kedl, and M.F. Mescher. 1999. CD8 
T cells become nonresponsive (anergic) following activation
in the presence of costimulation. J. Immunol. 163:102–110.
60. Shrikant, P., A. Khoruts, and M.F. Mescher. 1999. CTLA-4
blockade reverses CD8  T cell tolerance to tumor by a
CD4  T cell- and IL-2-dependent mechanism. Immunity.
11:483–493.
61. Bird, J.J., D.R. Brown, A.C. Mullen, N.H. Moskowitz,
M.A. Mahowald, J.R. Sider, T.F. Gajewski, C.R. Wang, and
S.L. Reiner. 1998. Helper T cell differentiation is controlled
by the cell cycle. Immunity. 9:229–237.
62. Laouar, Y., and I.N. Crispe. 2000. Functional flexibility in T
cells: independent regulation of CD4  T cell proliferation
and effector function in vivo. Immunity. 13:291–301.